Similar Papers

Paper Title
Journal
Date
Author
Macular infarction as a presenting sign of systemic lupus erythematosus.
Jean Shein ... Shantan Reddy
Retinal cases & brief reports | VOL. 2
Jean Shein, et. al.Jean Shein ... Shantan Reddy
01 Jan 2008
Cutaneous Leukocytoclastic Vasculitis as the Presenting Sign of Systemic Lupus Erythematosus
Bianca Biglione ... Daniela Kroshinsky
The American Journal of Medicine | VOL. 136
Bianca Biglione, et. al.Bianca Biglione ... Daniela Kroshinsky
08 Dec 2022
Unilateral CRAO as the presenting clinical sign of systemic lupus erythematosus
Yuli Lim ... Shaheen Kavoussi
American Journal of Ophthalmology Case Reports | VOL. 29
Yuli Lim, et. al.Yuli Lim ... Shaheen Kavoussi
30 Jan 2023
Clinical and immunological features of primary and secondary antiphospholipid syndrome
T M Reshetnvak ... A V Volkov
Rheumatology Science and Practice | VOL. 0
T M Reshetnvak, et. al.T M Reshetnvak ... A V Volkov
15 Aug 2004
View more papers

More From: Ophthalmology Retina

Paper Title
Journal
Date
Author
Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis
Dominic Wei Ting Yap ... Chui Ming Gemmy Cheung
Ophthalmology Retina | VOL. -
Dominic Wei Ting Yap, et. al.Dominic Wei Ting Yap ... Chui Ming Gemmy Cheung
01 Jan 2025
Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab (Ophthalmol Retina. 2024;8:733–743)
Wan-Ju Annabelle Lee
Ophthalmology Retina | VOL. -
Wan-Ju Annabelle LeeWan-Ju Annabelle Lee
01 Jan 2025
Reply
Cindy X Cai ... George Hripcsak
Ophthalmology Retina | VOL. -
Cindy X Cai, et. al.Cindy X Cai ... George Hripcsak
01 Jan 2025
Yasunari Nodules: A Diagnostic Criterion for Neurofibromatosis Type 1
Alba Gómez-Benlloch ... Stephany Carrillo
Ophthalmology Retina | VOL. -
Alba Gómez-Benlloch, et. al.Alba Gómez-Benlloch ... Stephany Carrillo
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.